KRAS and non-small cell lung carcinoma: The incidence of KRAS G12D mutation in NSCLC is approximately 4%, accounting for 15% of all KRAS mutations.[20,21] Patients with G12D mutations had significantly lower median PD-L1 TPS expression than those with non-G12D mutations (1% vs 5%, P = .002).